Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation

The vision of a precision medicine–guided approach to novel cancer drug development is challenged by high intratumor heterogeneity and interpatient diversity. This complexity is rarely modeled accurately during preclinical drug development, hampering predictions of clinical drug efficacy. To address...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Res
Egile Nagusiak: Frazier, Jason P., Bertout, Jessica A., Kerwin, William S., Moreno-Gonzalez, Alicia, Casalini, Joey R., Grenley, Marc O., Beirne, Emily, Watts, Kori L., Keener, Andy, Thirstrup, Derek J., Tretyak, Ilona, Ditzler, Sally H., Tripp, Chelsea D., Choy, Kevin, Gillings, Sarah, Breit, Megan N., Meleo, Karri A., Rizzo, Vanessa, Herrera, Chamisa L., Perry, James A., Amaravadi, Ravi K., Olson, James M., Klinghoffer, Richard A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546104/
https://ncbi.nlm.nih.gov/pubmed/28364003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-0084
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak